ProfileGDS5678 / 1452236_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 81% 77% 79% 77% 81% 81% 79% 80% 79% 80% 79% 78% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6110580
GSM967853U87-EV human glioblastoma xenograft - Control 25.7749781
GSM967854U87-EV human glioblastoma xenograft - Control 35.2701677
GSM967855U87-EV human glioblastoma xenograft - Control 45.6523579
GSM967856U87-EV human glioblastoma xenograft - Control 55.2324877
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5626281
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6002281
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5193679
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.634880
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5190979
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6486980
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5003379
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3611478
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4648879